

Viatriis 2021 Sustainability Report Highlights

We work to empower people worldwide to live healthier at every stage of life.



Sustainability is fundamental to the VIATRIS™ mission. We strive to advance responsible and sustainable operations and leverage our collective expertise to empower people worldwide to live healthier at every stage of life, recognizing that our actions affect the stakeholders and communities we serve.

As a signatory to the UN Global Compact (UNGC), we believe companies can be a force for good, and it is essential that we do our part to help enable potential solutions to some of society's most pressing challenges. As part of advancing our commitments and work in 2021, we endorsed the Women's Empowerment Principles and signed on to the UNGC CEO Water Mandate. To further progress our work, we have set initial companywide goals in the areas of patient access, the environment, and diversity, equity and inclusion (DE&I), presented on the next page.

Viatriis at a Glance 2021

>80 Billion across **>165**
doses sold countries and territories

>1,400
approved molecules

~100 countries reached³
Based on the Access to Medicine Foundation's list of countries

Emerging Markets



Developed Markets



Japan, Australia and New Zealand (JANZ)



Greater China



Products in development by region¹

70

210

65

30

Products pending approval by region²

1,050

530

10

15

~500 Million
doses of medicine donated

~37,000 across **70+**
colleagues countries

~3,000
R&D, regulatory, clinical and medical experts



2021 CDP Scores

Water security **B**
Climate change **B-**



STAY CONNECTED:



Our Initial Sustainability Goals

These priority areas and initial goals support our sustained operations and relevance, our contribution to advancing the UN's Sustainable Development Goals for 2030, and help us proactively address evolving expectations from stakeholders.

ACCESS



- Provide antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.
- Impact 100 million patients via healthcare professional (HCP) education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

DE&I



- Engage at least 90% of employees globally on diversity, equity and inclusion learning by the end of 2023.
- Increase diversity in management:
 - Increase Women's representation in senior management globally to at least 35% by the end of 2027.
 - At least double Black representation in all management levels in the U.S. by the end of 2027.
 - At least double Hispanic/Latinx representation in senior management in the U.S. by the end of 2027.

ENVIRONMENT



- Reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030¹ and reduce Scope 3 GHG emissions covering purchase goods and services, capital goods, fuel and energy related alternatives and upstream transportation and distribution 25% by 2030.⁴ These near-term targets have been submitted to the Science Based Targets initiative (SBTi) for review and validation.
- Perform water risk assessments for all locations in high or extremely-high water risk areas as identified by the World Resource Institute and identify appropriate water conservation initiatives by 2025.
- Achieve a 50% increase in the number of zero landfill locations by 2030.⁴

Partnerships⁵



Business partnerships, memberships, and philanthropic collaborations help us reach patients and communities worldwide.

Awards and Recognitions



Viatrix is a signatory to the UN Global Compact and supports the global sustainable development agenda for 2030.



ABOUT VIATRIS

Viatrix empowers people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to improve patient health. We believe in healthcare not as it is, but as it should be. Because of our unwavering belief that better access leads to better health, we leverage our best-in-class manufacturing and scientific expertise and proven commercial capabilities to bring quality medicines to patients when and where they need them.

Learn more about our commitment to corporate social responsibility in our [2021 Sustainability Report](#).

RELATED SOURCES:

- ¹ Numbers have been rounded, Unique Molecule + form in Commercial segment
- ² Numbers have been rounded, Molecule + Form + Country
- ³ The Access to Medicine Foundation
- ⁴ From 2020 as a baseline
- ⁵ List not exhaustive

